Related Experiment Video

Updated: May 6, 2026

Novel and Innovative Hybrid Technique for Type A Aortic Dissection
06:26

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

1.4K

The Tryton Side Branch Stent™ for the treatment of coronary bifurcation lesions

Maik J Grundeken1, Pieter R Stella, Joanna J Wykrzykowska

  • 1Department of Cardiology, Academic Medical Center - University of Amsterdam, Room B2-213, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Expert Review of Medical Devices
|October 30, 2013
PubMed

Insights

Percutaneous coronary interventions (PCI) for coronary bifurcation lesions are challenging. The Tryton Side Branch Stent shows promising results, potentially improving outcomes compared to standard treatments.

Area of Science:

  • Interventional Cardiology
  • Cardiovascular Devices
  • Biomedical Engineering

Background:

  • Coronary bifurcation lesions represent a significant subset of percutaneous coronary interventions (PCI), accounting for about 15% of procedures.
  • Despite advancements in PCI, bifurcation lesions are associated with poorer clinical outcomes compared to non-bifurcation lesions.
  • Dedicated bifurcation devices have been developed to mitigate these adverse events.

Purpose of the Study:

  • To evaluate the clinical outcomes of the Tryton Side Branch Stent used in conjunction with a main branch stent for treating coronary bifurcation lesions.
  • To compare the Tryton stent strategy against standard side branch balloon angioplasty within the context of a randomized trial.

Main Methods:

  • The study involves the pivotal Tryton IDE randomized trial.
  • The trial compares the Tryton Side Branch Stent strategy against provisional single stent strategy for side branch treatment in bifurcation lesions.
  • Data from multiple registries and a pooled analysis of 900 patients using the Tryton stent have informed the study.

Main Results:

  • Previous registries and pooled analyses involving 900 patients demonstrated promising clinical outcomes with the Tryton stent for bifurcation PCI.
  • The ongoing Tryton IDE trial is designed to rigorously assess the efficacy and safety of this dedicated bifurcation device.

Conclusions:

  • The Tryton Side Branch Stent is a dedicated device designed to improve outcomes in coronary bifurcation PCI.
  • The Tryton IDE trial aims to challenge the current standard of care, the provisional single stent strategy, for treating these complex lesions.

More Related Videos

4D Printed Bifurcated Stents with Kirigami-Inspired Structures06:52

4D Printed Bifurcated Stents with Kirigami-Inspired Structures

Published on: July 25, 2019

7.8K

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
539
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
618
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
659
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
619